School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; Department of Oncology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
Department of Oncology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
Int J Biol Macromol. 2022 Dec 31;223(Pt A):931-938. doi: 10.1016/j.ijbiomac.2022.11.084. Epub 2022 Nov 11.
MicroRNAs (miRNAs), useful biomarkers for cancer diagnosis, play an important role in tumorigenesis and progression, but many of the current analysis methods can suffer from excessive protease dependence, being time-consuming and unsatisfactory performance. Therefore, a reliable sensing strategy for the protein-free, ultrasensitive analysis of tumor-associated miRNAs is desired. The proposed dual-walker biosensing strategy based on an entropy-driven catalytic (EDC) walker coupled with a smart-responsive DNAzyme walker was demonstrated for the dual-amplification detection of miRNA-21. Namely, the target miRNA-21 initiates the three-stranded substrate complex of the traditional EDC circuit to release the input trigger of the Dz walker, which recognizes the circular binding domain to restore the cleavage activity of the DzS-AuNP walker. The fluorescence signal continuously released from the AuNPs was recorded by a fluorescence reader for miRNA-21 sensing. The optimized dual-walker exhibited appreciable sensitivity with a detection limit of 70 fM, satisfactory flexibility, fine specificity and ideal stability for clinical serum sample assays. The proposed strategy may open a new avenue for the development of powerful DNA molecular tools for cancer diagnosis.
微小 RNA(miRNAs)是癌症诊断的有用生物标志物,在肿瘤发生和发展中发挥重要作用,但许多现有的分析方法可能过度依赖蛋白酶,耗时且性能不佳。因此,需要一种无蛋白的、超灵敏的肿瘤相关 miRNAs 分析的可靠传感策略。所提出的基于熵驱动催化(EDC)行走物与智能响应 DNA 酶行走物的双行走物生物传感策略被证明可用于 miRNA-21 的双重扩增检测。即,靶 miRNA-21 启动传统 EDC 电路的三链底物复合物,以释放 Dz 行走物的输入触发,该触发物识别圆形结合域以恢复 DzS-AuNP 行走物的切割活性。荧光阅读器记录来自 AuNPs 的连续释放的荧光信号,用于 miRNA-21 感测。优化后的双行走物具有可检测限为 70 fM 的优异灵敏度、令人满意的灵活性、良好的特异性和理想的稳定性,可用于临床血清样本分析。该策略可能为癌症诊断的强大 DNA 分子工具的开发开辟新途径。